In the latest trading session, 1.19 million Terns Pharmaceuticals Inc (NASDAQ:TERN) shares changed hands as the company’s beta touched -0.37. With the company’s most recent per share price at $6.55 changing hands around $0.4 or 6.50% at last look, the market valuation stands at $556.35M. TERN’s current price is a discount, trading about -74.05% off its 52-week high of $11.40. The share price had its 52-week low at $4.32, which suggests the last value was 34.05% up since then. When we look at Terns Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.58 million shares, with the 3-month average coming to 2.07 million.
Analysts gave the Terns Pharmaceuticals Inc (TERN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended TERN as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Terns Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.3.
Terns Pharmaceuticals Inc (NASDAQ:TERN) trade information
Instantly TERN is in green as seen in intraday trades today. With action 13.13%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 0.92%, with the 5-day performance at 13.13% in the green. However, in the 30-day time frame, Terns Pharmaceuticals Inc (NASDAQ:TERN) is -5.62% down. Looking at the short shares, we see there were 3.98 million shares sold at short interest cover period of 3.16 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 45.42% from its recent market value. According to analyst projections, TERN’s forecast low is 7 with 26 as the target high. To hit the forecast high, the stock’s price needs a -296.95% plunge from its current level, while the stock would need to soar -6.87% for it to hit the projected low.
Terns Pharmaceuticals Inc (TERN) estimates and forecasts
Data shows that the Terns Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 11.39% over the past 6 months, a 3.94% in annual growth rate that is considerably lower than the industry average of 17.60%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -12.40%. The 2024 estimates are for Terns Pharmaceuticals Inc earnings to increase by 4.65%.
TERN Dividends
Terns Pharmaceuticals Inc is expected to release its next quarterly earnings report in January.
Terns Pharmaceuticals Inc (NASDAQ:TERN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.14% of Terns Pharmaceuticals Inc shares while 97.72% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 97.86%. There are 97.72% institutions holding the Terns Pharmaceuticals Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 10.2326% of the shares, roughly 7.62 million TERN shares worth $51.89 million.
VIVO CAPITAL, LLC holds the second largest percentage of outstanding shares, with 8.3038% or 6.18 million shares worth $42.11 million as of 2024-06-30.
Among Mutual Funds, the top two as of Aug 31, 2024 were iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. With 1.56 shares estimated at $10.14 million under it, the former controlled 1.83% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 1.52% of the shares, roughly 1.29 shares worth around $8.43 million.
